S. Takemoto

发表

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report

Y. Obase, M. Fukuda, H. Taniguchi, 2021, Thoracic cancer.

The efficacy of magnesium in preventing renal dysfunction due to high-dose cisplatin for treatment of thoracic tumor

M. Shimada, M. Fukuda, Shuntaro Sato, 2016 .

Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.

S. Kohno, H. Soda, S. Tomari, 2010, Lung cancer.

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

M. Fukuda, Shuntaro Sato, H. Mukae, 2016, Cancer Chemotherapy and Pharmacology.

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer

Y. Obase, M. Shimada, M. Fukuda, 2019, Thoracic cancer.

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA

M. Fukuda, Shuntaro Sato, H. Mukae, 2019, Thoracic cancer.

Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non‐squamous non‐small cell lung cancer

M. Shimada, M. Fukuda, H. Taniguchi, 2017, Thoracic cancer.

Running Title : Pharmacokinetic parameters of gefitinib as predictors Clinical Trial Registration

M. Fukuda, Shuntaro Sato, H. Mukae, 2018 .

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

S. Yano, K. Takayama, J. Uchino, 2021, Translational lung cancer research.

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer

K. Ashizawa, Kazuma Kobayashi, M. Fukuda, 2017, Thoracic cancer.

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study

M. Shimada, M. Fukuda, H. Taniguchi, 2020, Thoracic cancer.

Life-threatening toxicity in a patient with UGT1A1*6 heterozygous polymorphism after irinotecan-based chemotherapy: a case report

K. Ashizawa, Y. Hasegawa, M. Fukuda, 2014 .

Evaluation of a Triage Checklist for Mild COVID-19 Outpatients in Predicting Subsequent Emergency Department Visits and Hospitalization during the Isolation Period: A Single-Center Retrospective Study

T. Nabeshima, K. Morita, K. Ariyoshi, 2022, Journal of clinical medicine.

E cacy of S-1 after Pemetrexed in Patients with Non-small Cell Carcinoma: A Retrospective Multi- institutional Analysis

S. Takemoto, 2020 .

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor

K. Ashizawa, M. Shimada, M. Fukuda, 2021, Journal of clinical medicine.

Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases

M. Shimada, H. Mukae, Yosuke Dotsu, 2022, Thoracic cancer.

Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer

M. Shimada, M. Fukuda, H. Taniguchi, 2019, Cancer Chemotherapy and Pharmacology.

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis

M. Fukuda, H. Taniguchi, H. Mukae, 2021, Thoracic cancer.

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study

M. Fukuda, H. Taniguchi, H. Mukae, 2019, Thoracic cancer.

Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer

M. Fukuda, S. Kohno, K. Nakatomi, 2015, Chemotherapy.

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

T. Mitsudomi, S. Yano, K. Takayama, 2022, Cancer science.

Heterogeneity of EGFR mutations in a patient treated with gefitinib as neo-adjuvant chemotherapy

M. Fukuda, J. Fukuoka, S. Kohno, 2015 .

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation

Y. Obase, K. Ashizawa, M. Fukuda, 2020, Thoracic cancer.

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study

M. Shimada, M. Fukuda, H. Mukae, 2022, Thoracic cancer.

[Trends in Outpatient Chemotherapy for Thoracic Oncology].

K. Ashizawa, Kazuma Kobayashi, M. Fukuda, 2020, Gan to kagaku ryoho. Cancer & chemotherapy.

Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4

Y. Obase, K. Ashizawa, M. Fukuda, 2016, Supportive Care in Cancer.

Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization

Shota Nakashima, H. Mukae, H. Soda, 2023, Thoracic cancer.

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

M. Fukuda, S. Kohno, K. Tsukamoto, 2013, Cancer Chemotherapy and Pharmacology.

Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma

Masashi Iwasaki, H. Mukae, H. Yamaguchi, 2023, Frontiers in Immunology.

Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial

M. Kusumoto, M. Ando, Y. Kondoh, 2022, European Respiratory Journal.

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial

J. Uchino, H. Kimura, K. Yoshimura, 2023, The oncologist.

Pulmonary phaeohyphomycosis due to Exophiala dermatitidis in a patient with pulmonary non-tuberculous mycobacterial infection.

Y. Obase, M. Tashiro, K. Yanagihara, 2023, Journal of Infection and Chemotherapy.

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer

S. Yano, T. Sen, H. Mukae, 2022, Cancer science.

Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α

H. Mukae, H. Soda, Susumu Fukahori, 2017, Internal medicine.

Disseminated Mycobacterium genavense Infection Mimicking Sarcoidosis: A Case Report and Review of Literature on Japanese Patients

Y. Obase, Y. Sasaki, Kazumasa Fukuda, 2023, Microorganisms.

Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy

Y. Obase, M. Fukuda, H. Mukae, 2022, Lung cancer management.

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study

M. Shimada, H. Mukae, H. Soda, 2023, Thoracic cancer.

Impact of Administering Intravenous Azithromycin within 7 Days of Hospitalization for Influenza Virus Pneumonia: A Propensity Score Analysis Using a Nationwide Administrative Database

Y. Obase, S. Matsuda, K. Fushimi, 2023, Viruses.

Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature

Y. Obase, H. Mukae, S. Tsutsui, 2023, BMC Pulmonary Medicine.

Risk factor of non-tuberculous Mycobacterium infection in patients with rheumatoid arthritis and other autoimmune diseases receiving biologic agents: A multicenter retrospective study.

K. Yanagihara, S. Kawashiri, K. Izumikawa, 2024, Respiratory investigation.

Development of a score model to predict long-term prognosis after community-onset pneumonia in older patients.

K. Yanagihara, N. Hosogaya, T. Miyazaki, 2024, Respirology.